Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP)
2024-517032-22-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Apr 2025
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 29
01
Overview
Phase 3, open-label, single-arm trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Sanofi. Primary endpoint: Safety: adverse events and clinically significant abnormalities. Planned start Apr 2025; status: authorised.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2024-517032-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517032-22-00.